TAVR in Low-Risk Aortic Stenosis: 2026 Clinical Review
5-year data from Evolut Low Risk and PARTNER 3 confirm TAVR is noninferior to surgery in low-risk aortic stenosis patients. A 2026 review of outcomes, durability, real-world evidence, and lifetime management considerations.